Figure 4 | Scientific Reports

Figure 4

From: PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Figure 4

Kaplan–Meier survival curves of distant metastasis-free survival (DMFS) in relation to PD-L1 expression based on PD-L1 antibody-IHC assays in patients with breast cancer. (a) Patients with negative PD-L1 expression based on the 22C3-IHC assay were associated with poor DMFS (HR 2.867, 95% CI 1.247–6.589, P = 0.0131, log-rank test). (b, c) DMFS did not significantly differ based on SP142- and SP263-IHC assay results.

Back to article page